IPO
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers.
Medexus Pharmaceuticals Inc. announced that it plans to host a conference call at 8:00 AM Eastern Time on Monday, December 2, 2019 to discuss the Company’s financial results for the second quarter ended September 30, 2019, as well as the Company’s corporate progress and other developments.
On 5 November 2019, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 and the Commission Delegated Regulation 2016/1052 of 8 March 2016.
Avadim Health, Inc. announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.
Tyme Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced it will ring the Nasdaq Opening Bell on Wednesday, November 27, to honor the many stakeholders who are committed to finding a cure for patients with pancreatic cancer during Pancreatic Cancer Awareness Month.
Surface Oncology announced it has secured a debt financing facility for up to $25 million from K2 HealthVentures, a healthcare-focused specialty finance company.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, reported financial and operating results for the fourth quarter and fiscal year ended August 31, 2019 and provided a business update.
Sorrento Therapeutics, Inc., confirmed that on November 23, 2019, it received an unsolicited, non-binding term sheet proposal submitted by two biopharmaceutical companies, to acquire all of the issued and outstanding shares of the Company for between $3.00 and $5.00 per share in cash.
Summary of webcast with Key Opinion Leaders on Indolent Systemic Mastocytosis
BONE THERAPEUTICS informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholder meeting will be held on Thursday 12 December 2019 at 10am CET, at the Company’s registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium.
PRESS RELEASES